Cargando…
MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)
BACKGROUND: Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy...
Autores principales: | Pavic, M., Niyazi, M., Wilke, L., Corradini, S., Vornhülz, M., Mansmann, U., Al Tawil, A., Fritsch, R., Hörner-Rieber, J., Debus, J., Guckenberger, M., Belka, C., Mayerle, J., Beyer, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788088/ https://www.ncbi.nlm.nih.gov/pubmed/35078490 http://dx.doi.org/10.1186/s13014-022-01988-6 |
Ejemplares similares
-
Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review
por: Vornhülz, Marlies, et al.
Publicado: (2022) -
Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial
por: Ristau, J., et al.
Publicado: (2022) -
MR-guidance in clinical reality: current treatment challenges and future perspectives
por: Corradini, S., et al.
Publicado: (2019) -
Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer
por: Schaule, J., et al.
Publicado: (2021) -
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)